首页> 美国卫生研究院文献>Diabetes Therapy >Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease

【2h】

Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease

机译：依帕列净与西格列汀和沙格列汀比较的成本-效果分析基于2型糖尿病和已确立的心血管疾病患者的心血管结果试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

The online version of this article (10.1007/s13300-019-00701-3) contains supplementary material, which is available to authorized users.

机译：本文的在线版本（10.1007 / s13300-019-00701-3）包含补充材料，可供授权用户使用。

著录项

期刊名称 Diabetes Therapy
作者
Mafalda Ramos; Volker Foos; Anastasia Ustyugova; Nikco Hau; Pranav Gandhi; Mark Lamotte;
展开▼
作者单位

展开▼
年(卷),期 2019(10),6
年度 2019
页码 -1
总页数 15
原文格式 PDF
正文语种
中图分类基础医学;
关键词
Cardiovascular outcomes; Cost-effectiveness; Diabetes type 2; Empagliglozin; Saxagliptin; Sitagliptin;

机译：心血管结果;成本效益;2型糖尿病;依格列珠蛋白;沙格列汀;西他列汀;

相似文献

外文文献
中文文献
专利

1. Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease [J] . Mafalda Ramos, Volker Foos, Anastasia Ustyugova, Diabetes therapy . 2019,第6期

机译：依帕列净与西格列汀和沙格列汀比较的成本-效果分析基于2型糖尿病和已确立的心血管疾病患者的心血管结果试验
2. Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial [J] . Kansal A., Reifsnider O. S., Proskorovsky I., Diabetic medicine: A journal of the British Diabetic Association . 2019,第11期

机译：2型糖尿病患者empagliflozin治疗的成本效益分析，并在EMPA-REM结果试验中建立心血管疾病
3. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease [J] . GreenJ.B., BethelM.A., PaulS.K., The American heart journal . 2013,第6期

机译：西格列汀（TECOS）对2型糖尿病和已确定的心血管疾病患者进行随机，对照试验评估心血管结局的原理，设计和组织
4. An explainable XGBoost–based approach towards assessing the risk of cardiovascular disease in patients with Type 2 Diabetes Mellitus [C] . Maria Athanasiou, Konstantina Sfrintzeri, Konstantia Zarkogianni, IEEE International Conference on Bioinformatics and Bioengineering . 2020

机译：一种可解释的XGBoost基方法，旨在评估2型糖尿病患者心血管疾病风险的方法
5. Health outcomes of patients with type 2 diabetes hospitalized with cardiovascular disease: An assessment of caregivers and glycemic control. [D] . Comellas, Mariceli. 2014

机译：患有心血管疾病的2型糖尿病患者的健康结局：护理人员和血糖控制的评估。
6. Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo‐controlled double‐blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi‐center placebo‐controlled double‐blind randomized trial [O] . Atsushi Tanaka, Michio Shimabukuro, Noritaka Machii, 2020

机译：次要分析评估Empagliflozin对2型糖尿病患者内皮功能的深刻作用：Empagliflozin对心血管高风险糖尿病内皮功能的安慰剂对照双盲随机作用Mellitus：多中心安慰剂控制双盲随机试验
7. Cost-effectiveness analysis of empagliflozin in the treatment of patients with type 2 diabetes and established cardiovascular disease in Italy, based on the results of the EMPA-REG OUTCOME study [O] . Sergio Iannazzo, Edoardo Mannucci, Odette Reifsnider, 2017

机译：根据Empa-REG OUTCOmE研究的结果，在意大利治疗2型糖尿病和确诊心血管疾病的依帕列净的成本效益分析

Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease

摘要

著录项

相似文献

相关主题

期刊订阅